The global liquid biopsy market is projected to grow significantly, with an estimated value of USD 35.3 billion by 2033, up from USD 10.3 billion in 2023, reflecting a compound annual growth rate ...

If melanoma spreads, there are various therapies that can be used. However, there is still insufficient research into who ...

Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results of a clinical study which show that its Parsortix system could be ...

Analysts have set 12-month price targets for OncoCyte, revealing an average target of $4.38, a high estimate of $5.00, and a ...

INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALSThe study investigated 123 metastatic ovarian cancer ...

have discovered that a specific liquid biopsy biomarker harbors the potential to identify the effectiveness of a treatment at an early stage. This could enable a more individualized treatment for ...

An analyst from Goldman Sachs has decided to maintain their Buy rating on Guardant Health, which currently sits at a price ...

Q1 2024 Earnings Call May 10, 2024 Guardant Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end ...

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: ...

They are working on finding a breast cancer signature through liquid biopsy, an innovative cancer screening test that detects tumour DNA circulating in the body using a sample of blood. This ...

Having examined the options trading patterns of Guardant Health, our attention now turns directly to the company. This shift ...

Medicare is currently barred from covering drugs for weight losses purposes. But roughly 61% of adults say they think ...